Centurion Res Share Discussion Threads

[antonio palocci] 11/9/2007 15:23

What an excellant cheap company. About now is the time to buy imo.

[loafofbread] 11/9/2007 14:20

Anyone hold out any hope for Thursday? (staying above 50p that is)

[gbh2] 11/9/2007 09:11

On the other hand it could be as simple as too little work and too much spending at the top!

[iaincc] 11/9/2007 08:59

Good job the board stopped us poor shareholders from excercising our pre-emption rights !!

Maybe the capital raising is part of the sub-prime problem.

[volsung] 10/9/2007 16:47

It would be dead funny if the share price went down to 4p again. The graph would look hilarious. I suppose holders wouldn't like it though.

[dr biotech] 10/9/2007 16:43

The trial that is recruiting today, is the same trial that was mentioned last year.

So more delay and unsurprising misinterpretation from QAZ, although in this case you could partially blame poor worded statement last year from the less than impressive management,

However it could be said that Neil Clarks comments today

"I am very pleased to report that CeNeS has commenced the first Phase II study under the co-development agreement with Ergomed".

would have been a clue.

[vow] 10/9/2007 12:37

Much better short term bet is VER imo:

FDA INFORMS ENDO AND VERNALIS THAT NEW TARGET ACTION DATE ON FROVA(R) sNDA IS SEPT. 30, 2007

[qazwsx123] 10/9/2007 12:33

First collaborative CNS 5161 PII trial initiated in 2006 with Ergomed:

13/7/2006

Cenes Pharmaceutical CeNeS signs development/revenue sharing deal with Ergomed, begins Phase II Tests

"CeNeS Pharmaceuticals said it has signed a development and revenue sharing deal with Ergomed for its CNS 5161 painkiller and has begun Phase II studies for the treatment of diabetic neuropathic pain and cancer pain, due to report in 2007.

Under the development and revenue sharing deal, the companies are to
collaborate on a development programme for CNS 5161 which will involve five
further phase II trials in addition to the ones announced today".



...............................

Second collaborative CNS 5161 PII trial initiated in 2007 with Ergomed:

10/9/2007

CeNeS and ERGOMED Report Start of Recruitment for Phase II trial of CNS 5161 in Cancer Pain

"CeNeS and the ERGOMED Group today announced that they have initiated recruitment into a Phase II study of the potential new pain drug CNS 5161. CNS 5161 is being developed under a co-development deal signed in July 2006 between CeNeS and ERGOMED.

The Phase II dose-escalation study is designed to establish the optimal schedule for infusion of CNS 5161 in the management of cancer pain".

[dr biotech] 10/9/2007 12:24

It is reasonable to assume they have had the results to the previous PII trial started last year and used the data before commencing these new PII trials, but just did not announce the results.

No, its inconceivable that would have the results of the PII trials and are witholding what would be market sensitive information.

[qazwsx123] 10/9/2007 12:13

Dr_Biotech, actually, the announcement on 13/7/2006 made it clear they had begun Phase II studies for the treatment of diabetic neuropathic pain and cancer pain, with Ergomed; but there would be "five further phase II trials in addition to the ones announced today". The announcemnt today regarding commencement of another PII trial, thus presumably refers to one of the "five" PII trials mentioned last year. It is reasonable to assume they have had the results to the previous PII trial started last year and used the data before commencing these new PII trials, but just did not announce the results.

[dr biotech] 10/9/2007 11:15

This is already behind the schedule they made last year

For immediate releaseCeNeS and ERGOMED announce Revenue Sharing and Co-Development Agreement for CNS
5161 and commencement of two Phase II studies in diabetic neuropathic pain and
cancer painCeNeS, Cambridge, UK, ERGOMED, Frankfurt, Germany 13 July 2006CeNeS Pharmaceuticals (AIM:CEN), the Cambridge-based biopharmaceutical company,
announced today that it is commencing two Phase II studies with its novel NMDA
antagonist CNS 5161 in diabetic neuropathic pain and opioid refractory cancer
pain respectively. The studies are planned to report results in 2007.

[qazwsx123] 10/9/2007 09:28

RNS Number:4868D
CeNeS Pharmaceuticals PLC
10th September 2007

CeNeS and ERGOMED Report Start of Recruitment for Phase II trial of CNS 5161 in Cancer Pain

CeNeS and the ERGOMED Group today announced that they have initiated recruitment into a Phase II study of the potential new pain drug CNS 5161. CNS 5161 is being developed under a co-development deal signed in July 2006 between CeNeS and ERGOMED.

The Phase II dose-escalation study is designed to establish the optimal schedule for infusion of CNS 5161 in the management of cancer pain. It will be carried out at a specialist oncology unit in Europe and will assess the safety, efficacy and phamacokinetic profile of CNS 5161 administered intravenously at various doses over 24 hours when added to opioids for the treatment of cancer pain with a neuropathic component.

The aim of the study is to identify the maximum tolerated dose and analgesic
efficacy of CNS 5161 in this patient population. The study will also assess any
correlation between changes in pain level and the plasma concentrations of CNS
5161. Up to 36 subjects will be enrolled sequentially and receive intravenous
infusions of CNS 5161 administered at 4 hour intervals at increasing dose
levels. The results of the study are planned to be available in H1 2008.

Pain is an inevitable consequence of most solid cancers. It has been estimated
that nearly three million patients in the seven major markets will require
treatment for cancer pain annually and that more than 70 per cent. of late stage cancer patients suffer from moderate to severe pain (Source Apex Healthcare).

Opioids are commonly used for managing moderate to severe cancer pain, but it
has been estimated that around 20 per cent. of patients will experience
opioid-refractory pain that has to be treated using alternative therapies.

Commenting on today's announcement Neil Clark, Chief Executive said, "I am very
pleased to report that CeNeS has commenced the first Phase II study under the
co-development agreement with Ergomed. Significant numbers of cancer patients
are not receiving adequate pain relief from existing pain drugs and this trial
will help establish the potential of CNS 5161 to provide an effective
alternative in the treatment of late stage cancer pain."

Miroslav Reljanovic, CEO of the ERGOMED Group added, "We are delighted to be
moving into the next stage of our co-development programme with CeNeS. CNS 5161
is a compound with tremendous potential and we look forward to working with
CeNeS to realise its full value."

[canford cliffs] 10/9/2007 07:25

looking good - hopefully more good news to follow, about time you got back in rescuer cos this stock owes you plenty!

[kalingalinga] 10/9/2007 07:16

Neil Clark, Chief Executive said, "I am very pleased

Well done Neil..

[joshkelly] 07/9/2007 15:15

back to have alook, the management is so stupid, cant beleived they consolidated the shares.

[piedro] 06/9/2007 09:25

If my calculations are correct they added 1,730,984 o/s

67,650,992 / 30 = 2,255,033
3,986,017 - 2,255,033 = 1,730,984........Q.E.D.

[kalingalinga] 06/9/2007 07:05

The Company was informed on 5 September 2007 that Gartmore Investment Limited
(GIL), Gartmore Fund Managers Limited (GFM) and Gartmore Global Partners (GGP)
had a total interest in 3,986,017 ordinary shares of 1p each in the capital of
the Company. This shareholding represents 18.2 per cent. of the issued share
capital of the Company.

[ygor705] 02/9/2007 12:28

Well Goldmans have gone so I think the shares should start to level out. This is a management not a product issue for me but with the developments over the past few months and I cant see the point in selling now. Not expecting too much too quickly but there are now comments on record that could come back and haunt management unless they get their fingers out soon. When it comes to individuals mud will stick.

[kalingalinga] 01/9/2007 08:22

A 3million shares sale at 2.6p...thats got to hurt...even if they came in on the placing

[gbh2] 31/8/2007 10:07

yep, the bid is the equivalent of 2.7p prior to consolidation and the offer just 2.76p!!

[dj hall] 31/8/2007 09:04

wow look, it goes up too!

[gbh2] 31/8/2007 08:52

And still the price drops but not to worry it'll not make any difference to the directors salaries!!!!!!!!!!!

[the_doctor] 30/8/2007 23:10

Haha.
Well, to be fair, its not exactly dressed up as AAA though, is it.

[alphorn] 30/8/2007 10:47

This is the equivalent of sub prime biotech.